# SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

> **NCT06622005** · PHASE1 · RECRUITING · sponsor: **Roswell Park Cancer Institute** · enrollment: 15 (estimated)

## Conditions studied

- Recurrent Multiple Myeloma
- Refractory Multiple Myeloma

## Interventions

- **DRUG:** Cxcr1/2 Inhibitor SX-682
- **DRUG:** Daratumumab and Recombinant Human Hyaluronidase
- **DRUG:** Carfilzomib
- **DRUG:** Dexamethasone
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Echocardiography
- **PROCEDURE:** Positron Emission Tomography
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging

## Key facts

- **NCT ID:** NCT06622005
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-10
- **Primary completion:** 2027-04-10
- **Final completion:** 2030-04-10
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06622005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06622005, "SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06622005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*